Tumor-associated antigens from autologous and allogeneic glioma cells (TAA (Glioma))

Tumor-associated antigens from autologous and allogeneic glioma cells represent a complex, heterogeneous mixture of proteins and peptides used as the active components in personalized immunotherapy for high-grade gliomas (Bota et al., 2022, Journal of Clinical Oncology). This approach, exemplified by the therapeutic vaccine ERC1671 (also known as Gliovac), utilizes both the patient's own tumor cells and cells from multiple donors to provide a broad array of targets for the immune system (Schijns et al., 2015, OncoImmunology). The biological function of these antigens is to serve as immunogens that, when processed by antigen-presenting cells, trigger a robust activation of cytotoxic T lymphocytes and B cells (ClinicalTrials.gov, NCT01903330). By incorporating allogeneic components, the therapy aims to overcome the inherent clonal heterogeneity and immunosuppressive microenvironment of glioblastoma multiforme. In clinical settings, these antigens are often administered alongside adjuvants like GM-CSF to enhance the recruitment and maturation of dendritic cells. The primary therapeutic goal is to induce a polyvalent anti-tumor response that can recognize and eliminate residual or recurrent glioma cells that may lack specific individual markers. This multi-antigen strategy is designed to reduce the likelihood of tumor escape through antigen loss, a common challenge in single-target therapies.

Other names

Glioma-associated antigensAutologous and allogeneic glioma cell lysateERC1671 antigensGliovac components

Induction of a polyvalent immune response through the presentation of a broad spectrum of autologous and allogeneic tumor-associated antigens to the host immune system.